Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610361 | 0.79 | KMT2A (0.46) | HSD17B10GAANPC1IDO1POLB | |
| SCHEMBL4757756 | 0.79 | LMNA (0.51) | MLYCDCYP1A2CYP2C9LMNAHTT | |
| SCHEMBL14072051 | 0.71 | POLB (0.34) | IKBKBCYP1A2CYP2C9LMNAHSD17B10 | |
| SCHEMBL3559531 | 0.69 | POLB (0.50) | CYP1A2CYP2C9LMNAHTTHSD17B10 | |
| SCHEMBL8764860 | 0.67 | MLYCD (0.44) | MLYCD | |
| SCHEMBL6294438 | 0.67 | MLYCD (0.40) | MLYCDIDO1 | |
| SCHEMBL8439996 | 0.65 | RET (0.38) | MLYCDCYP1A2CYP2C9LMNAHSD17B10 | |
| SCHEMBL4754963 | 0.65 | KDR (0.39) | HTTHSD17B10KMT2AMEN1 | |
| SCHEMBL28541453 | 0.65 | CYP1A2 (0.46) | MLYCDCYP1A2CYP2C9GAANPC1 | |
| SCHEMBL6614100 | 0.65 | KMT2A (0.37) | LMNAHTTGAANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022850-B2 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1628981-A2 | BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106492-A2 | BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | CCNB1, CCNB2, CCNI | MLYCD 2044/4885IKBKB 676/4885CYP1A2 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.